Abstract

AbstractAicardi–Goutières syndrome (AGS) is a rare disorder characterized by acquired microcephaly, cerebral calcifications, leukodystrophy, cerebral atrophy, chronic lymphocytosis, and increased interferon-α in cerebrospinal fluid. We report on two children affected by AGS type 2, caused by mutations in RNASEH2B. The first child had the mutation c.529G > A (p.A177T) and presented with an atypical and mild phenotype, with delayed psychomotor development, calcifications of the brain white matter and basal ganglia, and interferon signature positivity. The disease course was stable. The second child presented the mutation c.554T > G (p.V185G) and showed a later onset (15 months) and a more progressive clinical course with functional inability in the upper limbs, steppage gait, and irritability. Despite immunoglobulin therapy, she developed to progressive tetraparesis and severe hypotonia. This case report highlights that RNASEH2B mutation cannot fully predict the phenotype of AGS type 2 when a mutation c.529G > A occurs. Moreover, an earlier symptomatology may be not related to a more severe prognosis or to a partial or absent response to treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.